IQV vs MEDP
IQV: IQVIA is a global clinical research and healthcare intelligence platform that powers drug development and commercialization with AI-driven insights from 1.2 billion de-identified patient records. MEDP: Medpace is a specialized, full-service clinical contract research organization that helps biopharmaceutical and medical device companies accelerate the development of new therapies through every phase of clinical trials.
Side-by-side fundamentals
| Metric | IQV | MEDP | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $198.52 | $528.12 | |
| Market cap as of 2026-07-23 | $33.2B | $15.0B | |
| P/E as of 2026-07-23 | 23.98 | 32.69 | IQV lower |
| PEG as of 2026-07-23 | 2.51 | 2.71 | IQV lower |
| Net margin as of 2026-07-23 | +8.3% | +17.2% | MEDP higher |
| Gross margin as of 2026-07-23 | +33.0% | +29.1% | IQV higher |
| Operating margin as of 2026-07-23 | +13.2% | +21.0% | MEDP higher |
| ROE as of 2026-07-23 | +22.5% | +120.9% | MEDP higher |
| ROA as of 2026-07-23 | +4.7% | +24.8% | MEDP higher |
| Debt / equity as of 2026-07-23 | 2.55 | 0.00 | MEDP lower |
| Revenue growth (YoY) as of 2026-07-23 | +7.3% | +24.2% | MEDP higher |
| Revenue CAGR (3y) SEC XBRL | +4.2% | +20.1% | MEDP higher |
| Dividend streak (yrs) SEC XBRL | 1 | n/a | |
| Beta as of 2026-07-23 | 1.20 | 1.15 | |
| 1-year return as of 2026-07-22 close | +26.8% | +10.5% | IQV higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.